Adherence to oral antineoplastic therapy among patients with advanced or metastatic non-small cell lung cancer: a noninterventional, prospective study

Purpose We aimed to evaluate adherence to oral antineoplastic therapy (OAT) in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) and its potential relationship with several clinical outcomes. Methods Observational, prospective, multicenter study performed by 6 hospital...

Descripción completa

Detalles Bibliográficos
Autores: Mangues-Bafalluy, I, Bernardez, B, Martínez-Sesmero, JM, Navarro-Ruiz, A, Martín-Conde, MT, Rubio-Salvador, AR, Rius-Perera, J, Gilabert-Sotoca, M, López, MD, Mellén, AC
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2025
País:España
Institución:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
Repositorio:r-FISABIO. Repositorio Institucional de Producción Científica
OAI Identifier:oai:fisabio.fundanetsuite.com:p19301
Acceso en línea:https://fisabio.portalinvestigacion.com/publicaciones/19301
Access Level:acceso abierto
Palabra clave:Non-small cell lung cancer
Oral chemotherapy
Tyrosine kinase inhibitors
Anaplastic lymphoma kinase inhibitors
Adherence
Progression-free survival
id ES_d5d13fc8efdf73de92cee2ff1c7d7462
oai_identifier_str oai:fisabio.fundanetsuite.com:p19301
network_acronym_str ES
network_name_str España
repository_id_str
spelling Adherence to oral antineoplastic therapy among patients with advanced or metastatic non-small cell lung cancer: a noninterventional, prospective studyMangues-Bafalluy, IBernardez, BMartínez-Sesmero, JMNavarro-Ruiz, AMartín-Conde, MTRubio-Salvador, ARRius-Perera, JGilabert-Sotoca, MLópez, MDMellén, ACNon-small cell lung cancerOral chemotherapyTyrosine kinase inhibitorsAnaplastic lymphoma kinase inhibitorsAdherenceProgression-free survivalPurpose We aimed to evaluate adherence to oral antineoplastic therapy (OAT) in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) and its potential relationship with several clinical outcomes. Methods Observational, prospective, multicenter study performed by 6 hospital pharmacists in Spain. The primary outcome was the proportion of treatment adherence as evaluated by pill reconciliation during the 3-month active follow-up period. Those with an adherence > 80% were categorized as adherent. We performed multivariate Cox regression analyses to explore the factors associated with progression-free survival. Results From December 2019 to November 2022, we recruited 95 evaluable patients. Most of the patients received osimertinib (n = 45, 45.3%) or a first- or second-generation tyrosine kinase inhibitor (n = 23, 34.8%). Eighty-one patients showed greater than 80% adherence (85.3%, 95% CI 78.1% to 92.4%), as evaluated based on pill reconciliation; the mean (SD) adherence to OAT was 94.7% (11.4). According to the univariate analysis, the time to progression from study entry was significantly shorter among patients who were nonadherent than among those who were adherent (median 6.5 months vs. not reached, log-rank test p = 0.006; hazard ratio [HR] 2.619, 95% confidence interval [CI] 1.240-5.532). In the multivariate Cox regression analysis, nonadherence was the single factor associated with progression-free survival. Conclusion Consistent with previous evidence in this setting, our results suggest that adherence to oral antineoplastic treatment among patients with NSCLC is high. Whether this high rate of adherence translates to better clinical outcomes should be further evaluated in larger samples.SPRINGER2025info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://fisabio.portalinvestigacion.com/publicaciones/19301JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGYISSN: 01715216ISSNe: 14321335reponame:r-FISABIO. Repositorio Institucional de Producción Científicainstname:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)Inglésinfo:eu-repo/semantics/openAccessoai:fisabio.fundanetsuite.com:p193012026-06-11T12:45:17Z
dc.title.none.fl_str_mv Adherence to oral antineoplastic therapy among patients with advanced or metastatic non-small cell lung cancer: a noninterventional, prospective study
title Adherence to oral antineoplastic therapy among patients with advanced or metastatic non-small cell lung cancer: a noninterventional, prospective study
spellingShingle Adherence to oral antineoplastic therapy among patients with advanced or metastatic non-small cell lung cancer: a noninterventional, prospective study
Mangues-Bafalluy, I
Non-small cell lung cancer
Oral chemotherapy
Tyrosine kinase inhibitors
Anaplastic lymphoma kinase inhibitors
Adherence
Progression-free survival
title_short Adherence to oral antineoplastic therapy among patients with advanced or metastatic non-small cell lung cancer: a noninterventional, prospective study
title_full Adherence to oral antineoplastic therapy among patients with advanced or metastatic non-small cell lung cancer: a noninterventional, prospective study
title_fullStr Adherence to oral antineoplastic therapy among patients with advanced or metastatic non-small cell lung cancer: a noninterventional, prospective study
title_full_unstemmed Adherence to oral antineoplastic therapy among patients with advanced or metastatic non-small cell lung cancer: a noninterventional, prospective study
title_sort Adherence to oral antineoplastic therapy among patients with advanced or metastatic non-small cell lung cancer: a noninterventional, prospective study
dc.creator.none.fl_str_mv Mangues-Bafalluy, I
Bernardez, B
Martínez-Sesmero, JM
Navarro-Ruiz, A
Martín-Conde, MT
Rubio-Salvador, AR
Rius-Perera, J
Gilabert-Sotoca, M
López, MD
Mellén, AC
author Mangues-Bafalluy, I
author_facet Mangues-Bafalluy, I
Bernardez, B
Martínez-Sesmero, JM
Navarro-Ruiz, A
Martín-Conde, MT
Rubio-Salvador, AR
Rius-Perera, J
Gilabert-Sotoca, M
López, MD
Mellén, AC
author_role author
author2 Bernardez, B
Martínez-Sesmero, JM
Navarro-Ruiz, A
Martín-Conde, MT
Rubio-Salvador, AR
Rius-Perera, J
Gilabert-Sotoca, M
López, MD
Mellén, AC
author2_role author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Non-small cell lung cancer
Oral chemotherapy
Tyrosine kinase inhibitors
Anaplastic lymphoma kinase inhibitors
Adherence
Progression-free survival
topic Non-small cell lung cancer
Oral chemotherapy
Tyrosine kinase inhibitors
Anaplastic lymphoma kinase inhibitors
Adherence
Progression-free survival
description Purpose We aimed to evaluate adherence to oral antineoplastic therapy (OAT) in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) and its potential relationship with several clinical outcomes. Methods Observational, prospective, multicenter study performed by 6 hospital pharmacists in Spain. The primary outcome was the proportion of treatment adherence as evaluated by pill reconciliation during the 3-month active follow-up period. Those with an adherence > 80% were categorized as adherent. We performed multivariate Cox regression analyses to explore the factors associated with progression-free survival. Results From December 2019 to November 2022, we recruited 95 evaluable patients. Most of the patients received osimertinib (n = 45, 45.3%) or a first- or second-generation tyrosine kinase inhibitor (n = 23, 34.8%). Eighty-one patients showed greater than 80% adherence (85.3%, 95% CI 78.1% to 92.4%), as evaluated based on pill reconciliation; the mean (SD) adherence to OAT was 94.7% (11.4). According to the univariate analysis, the time to progression from study entry was significantly shorter among patients who were nonadherent than among those who were adherent (median 6.5 months vs. not reached, log-rank test p = 0.006; hazard ratio [HR] 2.619, 95% confidence interval [CI] 1.240-5.532). In the multivariate Cox regression analysis, nonadherence was the single factor associated with progression-free survival. Conclusion Consistent with previous evidence in this setting, our results suggest that adherence to oral antineoplastic treatment among patients with NSCLC is high. Whether this high rate of adherence translates to better clinical outcomes should be further evaluated in larger samples.
publishDate 2025
dc.date.none.fl_str_mv 2025
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://fisabio.portalinvestigacion.com/publicaciones/19301
url https://fisabio.portalinvestigacion.com/publicaciones/19301
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv SPRINGER
publisher.none.fl_str_mv SPRINGER
dc.source.none.fl_str_mv JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
ISSN: 01715216
ISSNe: 14321335
reponame:r-FISABIO. Repositorio Institucional de Producción Científica
instname:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
instname_str Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
reponame_str r-FISABIO. Repositorio Institucional de Producción Científica
collection r-FISABIO. Repositorio Institucional de Producción Científica
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869420758742073344
score 15,811543

Similares en LA Referencia